Company: INTS
Filing Date: 2025-04-25
Form Type: 424B4
Source: 0001628280-25-020056
Chunk: 22

Company: INTENSITY THERAPEUTICS, INC.
Filing Date: 2025-04-25
Form: 424B4
Chunk 22
---
 |   |      |     | $ | 0.75 |
| Net tangible book value per share as of December 31, 2024                                    |     | $ | 0.18 |     |   |      |
| Increase in net tangible book value per share attributable to new investors in this offering |     | $ | 0.08 |     |   |      |
| As adjusted net tangible book value per share after this offering                            |     |   |      |     | $ | 0.26 |
| Dilution in net tangible book value per share to new investors in this offering              |     |   |      |     | $ | 0.49 |

The table and discussion above are based on 15,122,873 shares of Common Stock outstanding as of December 31, 2024, and excludes the following:

• 141,996 Shares of Common Stock issued after December 31, 2024;

• 2,587,129 shares of Common Stock issuable upon the exercise of outstanding stock options with a weighted average exercise price of $6.14 per share;

• 2,041,563 shares of Common Stock issuable upon the exercise of outstanding warrants to purchase Common Stock with a weighted average exercise price of $4.32 per share; and

• 1,881,649 additional shares of the Common Stock reserved for future issuance under our equity incentive plans, plus 529,300 additional shares of the Common Stock reserved for future issuance under our equity incentive plans authorized on January 1, 2025.

Unless otherwise indicated, the discussion and table above assume no exercise of the outstanding options and warrants described above after December 31, 2024 and excludes the shares of Common Stock to be issued upon exercise of the Common Warrants offered in this offering.

To the extent that any outstanding warrants or options are exercised, new options or other equity awards are issued under our equity incentive plans, or we issue additional shares in the future, there will be further dilution to new investors participating in this offering. In addition, we may choose to raise additional capital due to market conditions or strategic considerations, even if we believe we have sufficient funds for our current or future operating plans. To the extent that additional capital is raised through the sale of equity or equity-based securities, the issuance of these securities could result in further dilution to our stockholders.

<div align='center'>15</div>

### DESCRIPTION OF CAPITAL STOCK
The following summary of the material terms of the capital